Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors
March 01, 2021 07:55 ET | Source: Enlivex Therapeutics Ltd Enlivex Therapeutics Ltd ISRAEL Collaboration aims to evaluate the potential of Allocetra™ in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies
Nes Ziona, Israel, March 01, 2021 (GLOBE NEWSWIRE) Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, and Mount Sinai Health System, one of the world’s leading academic health systems, today announced a new research collaboration for the development of clinical strategies for Allocetra™ with checkpoint inhibitors. Allocetra
Weill Cornell Medicine Establishes Graduate Programs at Houston Methodist apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Weill Cornell Medicine Establishes Graduate Programs at Houston Methodist
News provided by
Share this article
Weill Cornell Medicine (PRNewsFoto/Weill Cornell Medicine)
NEW YORK and HOUSTON, Feb. 26, 2021 /PRNewswire/ In an expansion of its top-ranked biomedical education curricula, Weill Cornell Medicine is launching an additional site for graduate programs at Houston Methodist for the 2021-22 academic year. This new site, offered by the Weill Cornell Graduate School of Medical Sciences at Houston Methodist, exemplifies the culmination of a decade-long endeavor to establish a biomedical pedagogical presence in Houston and builds on the 16-year academic affiliation between the two academic medical institutions.
Weill Cornell adds graduate programs at Houston Methodist
February 26, 2021
In an expansion of its biomedical education curricula, Weill Cornell Medicine is launching an additional site for graduate programs at Houston Methodist for the 2021-22 academic year.
This new site, offered by the Weill Cornell Graduate School of Medical Sciences at Houston Methodist, builds on the 16-year academic affiliation between the two academic medical institutions.
The Weill Cornell Graduate School of Medical Sciences, based in New York City, will offer doctorates at Houston Methodist in two areas of study: physiology, biophysics and structural biology (PBSB); and in neuroscience. Applications to the PBSB program will be accepted in February 2021 for the fall semester.
January 26, 2021
Researchers at Weill Cornell Medicine and Cornell’s Ithaca campus have developed a new computational method for studying genetic and environmental interactions and how they influence disease risk.
The research, published Jan. 7 in The American Journal of Human Genetics, makes the process of finding these interactions much less difficult and demonstrates their importance in determining body mass index and diabetes risk.
“Our study demonstrates that your genes matter and the environment matters and that the interaction of the two can increase risk for disease,” said co-senior author Olivier Elemento, a professor of computational genomics in computational biomedicine, professor of physiology and biophysics, associate director of the HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsaud Institute for Computational Biomedicine, and director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.